When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% ...

Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus.

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Biogen beat fourth-quarter earnings and sales expectations Wednesday, but Biogen stock could get hammered on its light earnings outlook.

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Bleakley Financial Group LLC raised its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 49.9% in the 4th quarter, according to the company in its most recent filing with the Securities & ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...